Effects of antiviral therapy on the reversal of liver fibrosis

Xin LUO; Ying QU; Xiaobo CAI; Lungen LU

doi:10.3969/j.issn.1001-5256.2022.11.032

Volume 38 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(11): 2596-2598

PDF( 1849 KB)

Effects of antiviral therapy on the reversal of liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2022.11.032

Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China

More Information

Corresponding author: LU Lungen, lungenlu1965@163.com(ORCID: 0000-0002-1533-4068)
Received Date: 2022-04-07
Accepted Date: 2022-07-06
Published Date: 2022-11-20

Abstract

Abstract

As an inevitable stage in the progression of various chronic liver diseases, liver fibrosis eventually develops into liver cirrhosis or cancer. Because viral infection is a major cause of liver fibrosis, antiviral therapy is critical in the seroconversion and reversal of liver fibrosis in viral hepatitis. This review summarizes the clinical effects and underlying molecular mechanisms of antiviral therapy in the pathological reversal of liver fibrosis, as well as the current limitations, with the goal of providing literature references for upcoming clinical and basic research.
- Liver Cirrhosis,
- Antiviral Agents,
- Pathologic Processes

FullText(HTML)

References(23)

References

[1]	GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398(10308): 1359-1376. DOI: 10.1016/S0140-6736(21)01374-X.
[2]	CHEN XF, ZHANG DJ, LUO XD, et al. Current status of the treatment of chronic hepatitis B[J]. J Clin Hepatol, 2021, 37(5): 1011-1015. DOI: 10.3969/j.issn.1001-5256.2021.05.004. 陈学福, 张东敬, 罗晓丹, 等. 慢性乙型肝炎的治疗现状[J]. 临床肝胆病杂志, 2021, 37(5): 1011-1015. DOI: 10.3969/j.issn.1001-5256.2021.05.004.
[3]	CAO W, CHEN HD, YU YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474.
[4]	PAROLA M, PINZANI M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65: 37-55. DOI: 10.1016/j.mam.2018.09.002.
[5]	EVERHART JE, WRIGHT EC, GOODMAN ZD, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial[J]. Hepatology, 2010, 51(2): 585-594. DOI: 10.1002/hep.23315.
[6]	BEDOSSA P, POYNARD T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group[J]. Hepatology, 1996, 24(2): 289-293. DOI: 10.1002/hep.510240201.
[7]	HO SY, WANG LC, HSU CY, et al. Metavir fibrosis stage in hepatitis C-Related hepatocellular carcinoma and association with noninvasive liver reserve models[J]. J Gastrointest Surg, 2020, 24(8): 1860-1862. DOI: 10.1007/s11605-020-04627-1.
[8]	CAMPANA L, IREDALE JP. Regression of liver fibrosis[J]. Semin Liver Dis, 2017, 37(1): 1-10. DOI: 10.1055/s-0036-1597816.
[9]	ZHANG BY, CHAI DP, WU YH, et al. Potential drug targets against hepatitis B virus based on both virus and host factors[J]. Curr Drug Targets, 2019, 20(16): 1636-1651. DOI: 10.2174/1389450120666190729115646.
[10]	MARCELLIN P, GANE E, BUTI M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J]. Lancet, 2013, 381(9865): 468-475. DOI: 10.1016/S0140-6736(12)61425-1.
[11]	SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65(5): 1438-1450. DOI: 10.1002/hep.29009.
[12]	JIANG XY, HUANG B, HUANG DP, et al. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy[J]. World J Gastroenterol, 2021, 27(11): 1101-1116. DOI: 10.3748/wjg.v27.i11.1101.
[13]	CHEN S, ZHOU J, WU X, et al. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B[J]. Hepatol Int, 2021, 15(3): 611-620. DOI: 10.1007/s12072-021-10162-1.
[14]	POYNARD T, MCHUTCHISON J, MANNS M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C[J]. Gastroenterology, 2002, 122(5): 1303-1313. DOI: 10.1053/gast.2002.33023.
[15]	KANDA T, GOTO T, HIROTSU Y, et al. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: A review[J]. Int J Mol Sci, 2019, 20(6): 1358. DOI: 10.3390/ijms20061358.
[16]	LUEDDE T, KAPLOWITZ N, SCHWABE RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance[J]. Gastroenterology, 2014, 147(4): 765-783. e4. DOI: 10.1053/j.gastro.2014.07.018.
[17]	ROEHLEN N, CROUCHET E, BAUMERT TF. Liver fibrosis: Mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9(4): 875. DOI: 10.3390/cells9040875.
[18]	PAQUISSI FC. Immunity and fibrogenesis: The role of Th17/IL-17 axis in HBV and HCV-induced chronic hepatitis and progression to cirrhosis[J]. Front Immunol, 2017, 8: 1195. DOI: 10.3389/fimmu.2017.01195.
[19]	FU Y, WU S, HU Y, et al. Mutational characterization of HBV reverse transcriptase gene and the genotype-phenotype correlation of antiviral resistance among Chinese chronic hepatitis B patients[J]. Emerg Microbes Infect, 2020, 9(1): 2381-2393. DOI: 10.1080/22221751.2020.1835446.
[20]	LI HJ, HE JS, HU SL, et al. The clinical efficacy of acoustic radiation force pulse imaging, transient elastography, aspartate aminotransferase and platelet ratio index in detecting the degree of liver fibrosis in patients with hepatitis B[J]. Clin J Med Offic, 2020, 48(9): 1090-1091, 1094. DOI: 10.16680/j.1671-3826.2020.09.35. 栗红江, 何久胜, 胡素玲, 等. 声辐射力脉冲成像技术、瞬时弹性成像技术及天冬氨酸氨基转移酶与血小板比率指数联合检测乙型肝炎肝纤维化程度临床效能[J]. 临床军医杂志, 2020, 48(9): 1090-1091, 1094. DOI: 10.16680/j.1671-3826.2020.09.35.
[21]	JI D, CHEN Y, SHANG Q, et al. Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B[J]. Am J Gastroenterol, 2021, 116(8): 1676-1685. DOI: 10.14309/ajg.0000000000001239.
[22]	SUN Y, WU X, ZHOU J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2582-2591. e6. DOI: 10.1016/j.cgh.2020.03.001.
[23]	SARRAZIN C. Treatment failure with DAA therapy: Importance of resistance[J]. J Hepatol, 2021, 74(6): 1472-1482. DOI: 10.1016/j.jhep.2021.03.004.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1022) PDF downloads(118)

Effects of antiviral therapy on the reversal of liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2022.11.032

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content